Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer Meeting Abstract


Authors: Cha, E. K.; Iyer, G.; Funt, S. A.; Regazzi, A. M.; Francis, J.; Heinemann, M. H.; Ostrovnaya, I.; Dalbagni, G.; Bajorin, D. F.; Bochner, B. H.; Rosenberg, J. E.
Abstract Title: Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
Meeting Title: 2020 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 38
Issue: 6 Suppl.
Meeting Dates: 2020 Feb 13-15
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2020-02-20
Language: English
ACCESSION: WOS:000529525900537
PROVIDER: wos
DOI: 10.1200/JCO.2020.38.6_suppl.510
Notes: Meeting Abstract: 510 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dean Bajorin
    664 Bajorin
  2. Guido Dalbagni
    327 Dalbagni
  3. Jasmine Helen Francis
    268 Francis
  4. Gopakumar Vasudeva Iyer
    359 Iyer
  5. Bernard Bochner
    473 Bochner
  6. Ashley Regazzi
    93 Regazzi
  7. Jonathan Eric Rosenberg
    525 Rosenberg
  8. Eugene K. Cha
    102 Cha
  9. Samuel Aaron Funt
    144 Funt